Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
Human microvascular endothelial cells treated with KH-CB19 (10 μM; 1 h) exhibit the inhibitory action of CLK on SR protein phosphorylation [1]. In A549 cells, KH-CB19 (50 μM; 6 hours) suppresses CLK4 destruction [2].
|
---|---|
Cell Assay |
Western blot analysis[1]
Cell Types: Human microvascular endothelial cells (HMEC-1) Tested Concentrations: 10 μM Incubation Duration: 1 hour Experimental Results: Phosphorylation of SRp75, SRp55 and SRp20 was diminished compared to non-TNF-α stimulated controls. The TNF-α-induced increase in phosphorylation was diminished for all analyzed SR proteins compared with TNF-α-stimulated controls. |
References |
[1]. Fedorov O, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
[2]. Artarini A, et al. Regulation of influenza A virus mRNA splicing by CLK1. Antiviral Res. 2019 Aug;168:187-196. |
Molecular Formula |
C15H13CL2N3O2
|
---|---|
Molecular Weight |
338.19
|
Exact Mass |
337.0385
|
CAS # |
1354037-26-5
|
Related CAS # |
KH-CB20;1354448-60-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(C(N1C)=C(/C(C#N)=C\N)C2=C1C(Cl)=C(Cl)C=C2)OCC
|
Synonyms |
KHCB19; KH CB19; KH-CB19
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~147.85 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9569 mL | 14.7846 mL | 29.5692 mL | |
5 mM | 0.5914 mL | 2.9569 mL | 5.9138 mL | |
10 mM | 0.2957 mL | 1.4785 mL | 2.9569 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.